Nitric Oxide innovations LLC will develop novel cardiac drug therapies. Oral formulations for specific drug indications where safety and efficacy are already established including ischemia and no obstructive coronary artery disease (INOCA), pulmonary hypertension, heart failure with preserved ejection fraction (HFpEF). Each segment has multi-billion dollar market with unmet needs.
1998 Nobel Prize in Physiology or Medicine
"For their discoveries concerning nitric oxide as a signaling molecule in the cardiovascular system"
"The discovery of nitric oxide and its function is one of the most important in the history of cardiovascular medicine."
- Valentine Fuster, M.D.
1998 President, American Heart Association
Head of Cardiology, Mount Sinai Hospital NYC
The Loss of
Nitric Oxide is Associated
Mortality, Risk Factors of Patients With Cardiac
Injury and COVID-19
Among the patients studied, the median (range) age was 64 (21-95) years, most (50.7%) were female, and the median time to symptom onset was 10 days (interquartile range [IQR]), 1-30). Of this group, 82 (19.7%) had some type of cardiac injury, and they were older than the cohort of patients without cardiac injury: Their median age was 74 (34-95) years compared with 60 (21-90) years.
It was apparent as the study went on that patients with cardiac injury and COVID-19 fared worse than the patients with COVID-19 but no history of cardiac injury. Here are some examples:
Most importantly, patients with a cardiac injury with diagnosed COVID-19, compared with patients
without cardiac injury, had a higher mortality rate (51.2% vs 4.5%) and risk of death.
Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China
March 25, 2020]. JAMA Cardiol. doi: 10.1001/jamacardio.2020.0950.
Conclusions: patients with symptoms of nitric oxide deficiency are more susceptible to
infection, have greater severity of disease, increased need for ventilation and
TEN TIMES HIGHER MORTALITY